Open Accessibility Menu

Coronavirus (COVID-19) Vaccine Update Click here to learn more.

For information about COVID-19 or to view additional resources, please click here.

Clinical Trial Information

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis.

Study Details

Main inclusion criteria:

  1. Chronic AD for at least 2 years with EASI ≥ 16 and IGA score ≥ 3. AD involvement ≥ 10% of body surface area.
     
  2. Documented recent history (within 6 months) of inadequate response to TCS.
     
  3. Documented recent history (within 6 months) of inadequate response to TCI if the patient has been using TCI.

Primary Sponsor:

Galderma

Prinicipal Investigator:

Dr. Karl Saardi

Contact Phone:

(202) 667-6160
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis. ntolstoy@mfa.gwu.edu

Interested in More Information

  • Please enter your first name.
  • Please enter your last name.
  • This isn't a valid email address.
    Please enter your email address.
  • This isn't a valid phone number.
    Please enter your phone number.
    You entered an invalid number.
  • Please enter your address.
  • Please enter your city.
  • Please enter your state.
  • Please enter your zip code.
  • (All Uppercase. No Spaces)